Capmatinib instructions, usage and dosage, side effects

Capmatinib (Capmatinib), as an innovative drug, is specially used to treat non-small cell lung cancer that has spread to other parts of the body or cannot be eradicated by surgery. However, this drug is not suitable for all patients with lung cancer. Capmatinib can only exert its best effect when the patient's cancer carries a special genetic marker, namely an abnormal "MET" gene. To ensure the suitability of the drug, doctors will conduct genetic testing on patients beforehand.

Mechanism of action: In-depth research shows that in many cancer types, Abnormal activation of c-Met is a common phenomenon, especially in non-small cell lung cancer. When skip mutations occur in MET exon 14, it creates a c-Met mutant that is missing a key regulatory domain. This mutation causes the protein's negative regulatory mechanism to fail, thereby triggering abnormal enhancement of downstream signals. Fortunately, capmatinib can precisely inhibit the phosphorylation process of wild-type and mutant c-Met, which is originally triggered by hepatocyte growth factor. The intervention of capmatinib effectively blocks c-Met-mediated signaling, thus inhibiting the proliferation and survival of c-Met-dependent tumor cells.

Medication Guide: For adult patients with non-small cell lung cancer, the recommended dosage is 400 mg twice daily, taken orally.

Side effects: Although capmatinib performs well in anti-cancer treatment, patients still need to be alert to possible side effects. If you develop an allergic reaction such as hives, difficulty breathing, or swelling of the face, lips, tongue, and throat, seek medical attention immediately. In addition, capmatinib may cause some serious adverse reactions, such as new or worsening cough, chest pain, difficulty breathing with fever and sputum production, persistent and severe nausea and vomiting, and signs of liver or pancreatic problems, such as loss of appetite, upper abdominal pain (which may radiate to the back), nausea, vomiting, rapid heartbeat, dark urine, or jaundice (yellowing of the skin or whites of the eyes). If you develop these symptoms, contact your doctor as soon as possible, as some adverse effects may require you to suspend or permanently stop cancer treatment. In addition to the serious side effects mentioned above, taking capmatinib may also cause common adverse reactions such as difficulty breathing, nausea, vomiting, loss of appetite, general weakness, fatigue, abnormal liver function tests, or edema of the hands and feet. Please note that these are only some of the possible side effects and that taking this medicine may cause other reactions not listed.

Medication Instructions: Before taking capmatinib, carefully read all directions on the drug label and packaging, and inform each doctor of your medical conditions, allergies, and all medications you are taking. Especially if you have had lung problems (other than lung cancer) or liver disease, be sure to tell your doctor.

For patients planning to receive this treatment, a pregnancy test may be required before treatment to ensure a negative result. Also, both men and women taking capmatinib should use birth control to prevent pregnancy because this drug may cause harm to the fetus. Contraceptive measures should be continued for at least one week after stopping the medication. If you become pregnant while taking this medicine, tell your doctor right away. In addition, breastfeeding should be avoided while taking the drug and for at least one week after stopping the drug.

Drug Storage Recommendations: To ensure the effectiveness of the drug, store capmatinib at room temperature, away from moisture and heat, and in the original packaging with a hygroscopic preservative.